Aurora Investment Counsel Makes New $2.29 Million Investment in DexCom, Inc. $DXCM

Aurora Investment Counsel purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 33,994 shares of the medical device company’s stock, valued at approximately $2,287,000.

A number of other institutional investors have also added to or reduced their stakes in DXCM. Andra AP fonden acquired a new stake in DexCom in the second quarter valued at approximately $26,000. Twin Peaks Wealth Advisors LLC bought a new position in shares of DexCom in the 2nd quarter valued at $26,000. SJS Investment Consulting Inc. boosted its holdings in shares of DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 384 shares in the last quarter. Financial Consulate Inc. acquired a new stake in shares of DexCom during the 3rd quarter valued at $29,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new stake in DexCom during the 2nd quarter worth $45,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Performance

Shares of DXCM opened at $73.08 on Friday. The firm has a market capitalization of $28.13 billion, a P/E ratio of 34.80, a P/E/G ratio of 1.42 and a beta of 1.49. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $91.87. The stock has a 50 day moving average price of $69.49 and a two-hundred day moving average price of $69.31. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The business had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same period last year, the business earned $0.45 EPS. The business’s revenue was up 13.1% on a year-over-year basis. Equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on DXCM shares. Canaccord Genuity Group set a $95.00 target price on DexCom and gave the company a “buy” rating in a research report on Friday, February 13th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $86.00 price objective (up previously from $84.00) on shares of DexCom in a research note on Friday, January 9th. Morgan Stanley reiterated an “overweight” rating on shares of DexCom in a research report on Monday, January 12th. Robert W. Baird set a $87.00 target price on shares of DexCom in a report on Friday, February 13th. Finally, Royal Bank Of Canada dropped their price target on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a research note on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $85.18.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.